GPR68 and pulmonary fibrosis: Given that GPCRs are the most common entity targeted by FDA-approved drugs [63] and that extracellular pH is decreased in pulmonary fibrosis [20,52,64], OGR1 represents an exciting, though challenging, potential therapeutic target for IPF.